PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas

PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas

Objective: The BRAF inhibitor, vemurafenib, has been widely used in the treatment of patients with melanoma-bearing BRAFV600E mutations. While the initial response to vemurafenib is usually excellent, the majority of patients eventually develop resistance and metastatic disease. However, the underly...

Full description

Bibliographic Details
Main Authors: Junling Shen, Jilong Yang, Lei Sang, Rui Sun, Weiyu Bai, Chao Wang, Yan Sun, Jianwei Sun
Format: Article
Language:English
Published: China Anti-Cancer Association 2022-08-01
Series:Cancer Biology & Medicine
Subjects:
stim1
pyk2
invadopodia
invasion
melanoma
vemurafenib
Online Access:https://www.cancerbiomed.org/content/19/8/1211

Internet

https://www.cancerbiomed.org/content/19/8/1211

Similar Items